Therefore, these scientifically confirmed health-beneficial effects prompted us to evaluate urolithin-A as a potential novel treatment option for acute campylobacteriosis in C. jejuni infected microbiota-depleted IL-10−/− mice. This evidence concerns the gene IL10 and campylobacteriosis.